Andrew Mark Pardoll
Co-FounderDr. Andrew Mark Pardoll, also known as Drew, MD, PhD, serves as Venture Partner of Catalio Capital Management, LP. He is Scientific Co-Founder & Member of Scientific Advisory Board of Tizona Therapeutics, Inc. He is Member of Scientific Advisory Board of Immunomic Therapeutics, Inc. He serves as the Member of Scientific Advisory of Normunity Inc. He is the Co-Founder and Director of Clasp Therapeutics Inc. He is a Member of Advisory Board at Tempest Therapeutics Inc. He serves as a Member of Scientific Advisory Board of Oncology at Amgen Inc. He serves as a Member of Scientific Advisory Board at Enara Bio Limited. He was a Member of Scientific Advisory Board at and Barinthus Biotherapeutics plc until 2024. He co-founded TRex Bio, Inc. in 2018. He is an Abeloff Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at Johns Hopkins University School of Medicine. Dr. Pardoll was Member of Scientific Advisory Board at Immunomic Therapeutics, Inc. since December 2017. He had been Member of Scientific Advisory Board at Dynavax Technologies Corporation since June 2018. Dr. Pardoll founded Jounce Therapeutics, Inc. in 2012. He served as a Board Observer of Aduro BioTech, Inc. He serves as the Chairman of Scientific Advisory Board at Aduro BioTech, Inc. and Compugen Ltd. He served as the Chairman of the Scientific Advisory Board at Cerus Corporation since May 2004. He served as a Director of DNAtrix, Inc. until March 2022. He had been Member of Advisory Board at Shattuck Labs, Inc. since November 2020. He serves as the Director at Dracen Pharmaceuticals, Inc. He had been a Member of Scientific Advisory Board at RAPT Therapeutics, Inc. since May 31, 2017, Compugen Ltd. since January 2014. He serves as a Member of Scientific Advisory Council at Cancer Research Institute, Inc. He has been a Member of Advisory Board at ISA Pharmaceuticals BV since October 15, 2013. He serves as a Member of Scientific Advisory Board of Five Prime Therapeutics, Inc. Immunexcite, Inc. and Jennerex. He served as a Member of Scientific and Medical Advisory Board at Mojave Therapeutics, Inc. He has served on the editorial boards of the Journal of the National Cancer Institute and Cancer Cell and has served as a Member of Scientific Advisory Boards for the University of Pennsylvania Human Gene Therapy Gene Institute, Biologic Resources Branch of the National Cancer Institute, Harvard-Dana Farber Cancer Center, Global Medical Products Corporation, Genencor Corporation, CellGenesys Corporation, the American Association of Clinical Oncology and the American Association of Cancer Research. He served as a Director at Aduro BioTech, Inc. He served as a Member of Scientific Advisory Board at Cerus Corporation since May 2004. For the past two decades, Dr. Pardoll has studied molecular aspects of immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system. He made seminal advances in immunology, including the discovery of new types of immune cells and regulatory mechanisms. He was the first to propose blockade of PD-1 for cancer therapy and his program led the clinical development of the first anti-PD-1 antibody. Dr. Pardoll is an internationally recognized authority in cancer immunology and immunotherapy. He is noted for demonstrating the central role of GM-CSF in stimulating dendritic cells in vivo. In addition, he is a Co-Inventor of cytokine-gene-transduced tumor vaccines. He is an inventor of a number of immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes-based cancer vaccines. Dr. Pardoll has published several papers as well as over 20 book chapters on the subject of T cell immunology and cancer vaccines. Dr. Pardoll was the Scientific Founder and Board Observer at Amplimmune, Inc. He served as a Director at Amplimmune, Inc. He is the Director of the Bloomberg Kimmel Institute for Cancer Immunotherapy and Director of the Cancer Immunology Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He worked for many years at the National Institutes of Health as a Medical Staff Fellow. Dr. Pardoll joined the departments of oncology and medicine in 1988. Dr. Pardoll has MD from Johns Hopkins School of Medicine in 1982, PhD from Johns Hopkins School of Medicine in 1982 and BA from Johns Hopkins University.
Positions
- Company NameTRex Bio, Inc.Stock CodeTRXBPositionCo-FounderColleagues
- MJMarion Johnston ErwinChairman & CEO
- JSJoel S. MarcusIndependent Director
- LBLaura BernerChief Operating Officer
- AZAli ZarrinChief Scientific Officer & Executive Director of Drug Discovery
- AMAndrew Mark PardollCo-Founder
- MJMichael Jay RossIndependent Director
- CGCarol G. GallagherLead Independent Director
- TATravis Alan CoyIndependent Director
- Company NameCompugen Ltd.Stock CodeCGENPositionChairman of Scientific Advisory Board
